MiMedx Group Inc. (NASDAQ:MDXG) shot up 3.4% during trading on Monday . The stock traded as high as $7.60 and last traded at $7.55, with a volume of 514,754 shares changing hands. The stock had previously closed at $7.30.

Several research firms have commented on MDXG. First Analysis downgraded shares of MiMedx Group from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $14.00 to $9.00 in a report on Wednesday, April 27th. Brean Capital reaffirmed a “buy” rating on shares of MiMedx Group in a report on Thursday, May 12th. Zacks Investment Research downgraded shares of MiMedx Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 27th. Finally, TheStreet downgraded shares of MiMedx Group from a “buy” rating to a “hold” rating in a report on Monday, April 25th. Three investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. MiMedx Group has an average rating of “Buy” and a consensus price target of $10.89.

The company has a market cap of $830.27 million and a PE ratio of 35.758. The firm’s 50 day moving average is $7.71 and its 200 day moving average is $7.90.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Tuesday, July 26th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.07 by $0.02. The company earned $57 million during the quarter, compared to the consensus estimate of $56.49 million. During the same period last year, the firm earned $0.05 EPS. The business’s quarterly revenue was up 25.5% compared to the same quarter last year. On average, equities analysts predict that MiMedx Group Inc. will post $0.23 EPS for the current year.

In related news, insider William Charles Taylor sold 29,112 shares of MiMedx Group stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $7.55, for a total value of $219,795.60. Following the completion of the sale, the insider now directly owns 612,316 shares in the company, valued at approximately $4,622,985.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

A number of hedge funds and institutional investors have recently made changes to their positions in the company. Rhumbline Advisers boosted its position in shares of MiMedx Group by 13.1% in the fourth quarter. Rhumbline Advisers now owns 129,375 shares of the company’s stock valued at $1,212,000 after buying an additional 15,005 shares during the last quarter. First Trust Advisors LP boosted its position in MiMedx Group by 573.5% in the fourth quarter. First Trust Advisors LP now owns 140,573 shares of the company’s stock worth $1,317,000 after buying an additional 119,701 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in MiMedx Group by 19.4% in the fourth quarter. Wells Fargo & Company MN now owns 1,041,546 shares of the company’s stock worth $9,759,000 after buying an additional 169,102 shares during the last quarter.

MiMedx Group, Inc (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.